Omeros (OMER) Accumulated Expenses (2010 - 2026)
Omeros recorded quarterly Accumulated Expenses of $9.7 million in Q1 2026, down 66.85% quarter-over-quarter from $29.4 million in Q4 2025, and down 1.4% year-over-year from $9.9 million in Q1 2025.
Omeros' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $9.7 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 1.4% year-over-year to $9.7 million; the TTM figure through Mar 2026 stood at $9.7 million (down 1.4% YoY), while the FY2025 annual figure was $29.4 million, up 231.39% from the prior year.
- Accumulated Expenses came in at $9.7 million for Q1 2026 at Omeros, down from $29.4 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $29.4 million in Q4 2025 to a low of $300000.0 in Q4 2022.
- A 5-year average of $13.0 million and a median of $8.9 million in 2024 frame the typical range for Accumulated Expenses.
- On a YoY basis, Accumulated Expenses climbed as much as 1566.67% in 2023 and fell as far as 68.73% in 2023.
- Omeros' Accumulated Expenses stood at $300000.0 in 2022, then jumped by 1566.67% to $5.0 million in 2023, then surged by 77.36% to $8.9 million in 2024, then surged by 231.39% to $29.4 million in 2025, then sank by 66.85% to $9.7 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $9.7 million, $29.4 million, and $25.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.74 Mn |
| Dec 31, 2025 | 29.39 Mn |
| Sep 30, 2025 | 25.75 Mn |
| Jun 30, 2025 | 26.28 Mn |
| Mar 31, 2025 | 9.88 Mn |
| Dec 31, 2024 | 8.87 Mn |
| Sep 30, 2024 | 23.25 Mn |
| Jun 30, 2024 | 27.97 Mn |
| Mar 31, 2024 | 8.80 Mn |
| Dec 31, 2023 | 5.00 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Jun 30, 2023 | 7.34 Mn |
| Mar 31, 2023 | 3.70 Mn |
| Dec 31, 2022 | 300,000.00 |
| Sep 30, 2022 | 3.70 Mn |
| Jun 30, 2022 | 23.48 Mn |
| Mar 31, 2022 | 2.50 Mn |
| Dec 31, 2021 | 500,000.00 |
| Sep 30, 2021 | 3.70 Mn |
| Jun 30, 2021 | 33.32 Mn |
| Mar 31, 2021 | 6.15 Mn |
| Dec 31, 2020 | 28.76 Mn |
| Sep 30, 2020 | 36.95 Mn |
| Jun 30, 2020 | 25.84 Mn |
| Mar 31, 2020 | 3.34 Mn |
| Dec 31, 2019 | 46.63 Mn |
| Sep 30, 2019 | 10.56 Mn |
| Jun 30, 2019 | 12.09 Mn |
| Mar 31, 2019 | 34.82 Mn |
| Dec 31, 2018 | 12.01 Mn |
| Sep 30, 2018 | 15.18 Mn |
| Jun 30, 2018 | 11.98 Mn |
| Mar 31, 2018 | 13.93 Mn |
| Dec 31, 2017 | 19.13 Mn |
| Sep 30, 2017 | 20.26 Mn |
| Jun 30, 2017 | 21.64 Mn |
| Mar 31, 2017 | 14.34 Mn |
| Dec 31, 2016 | 13.35 Mn |
| Sep 30, 2016 | 11.88 Mn |
| Jun 30, 2016 | 10.45 Mn |
| Mar 31, 2016 | 12.12 Mn |
| Dec 31, 2015 | 9.75 Mn |
| Sep 30, 2015 | 8.12 Mn |
| Jun 30, 2015 | 6.76 Mn |
| Mar 31, 2015 | 6.44 Mn |
| Dec 31, 2014 | 7.07 Mn |
| Sep 30, 2014 | 6.25 Mn |
| Jun 30, 2014 | 5.48 Mn |
| Mar 31, 2014 | 5.31 Mn |
| Dec 31, 2013 | 3.94 Mn |
| Sep 30, 2013 | 4.52 Mn |
| Jun 30, 2013 | 4.16 Mn |
| Mar 31, 2013 | 553,000.00 |
| Dec 31, 2012 | 4.76 Mn |
| Sep 30, 2012 | 1.31 Mn |
| Jun 30, 2012 | 6.02 Mn |
| Mar 31, 2012 | 5.30 Mn |
| Dec 31, 2011 | 694,000.00 |
| Sep 30, 2011 | 2.61 Mn |
| Jun 30, 2011 | 3.02 Mn |
| Dec 31, 2010 | 4.57 Mn |